- Home
- BRTX vs CWD Comparison
BRTX vs CWD Comparison
Compare BRTX & CWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRTX
- CWD
- Stock Information
- Founded
- BRTX 1997
- CWD 2009
- Country
- BRTX United States
- CWD United States
- Employees
- BRTX N/A
- CWD N/A
- Industry
- BRTX Managed Health Care
- CWD Real Estate
- Sector
- BRTX Health Care
- CWD Finance
- Exchange
- BRTX Nasdaq
- CWD Nasdaq
- Market Cap
- BRTX 12.2M
- CWD 12.1M
- IPO Year
- BRTX N/A
- CWD 2023
- Fundamental
- Price
- BRTX $1.71
- CWD $0.25
- Analyst Decision
- BRTX Strong Buy
- CWD
- Analyst Count
- BRTX 1
- CWD 0
- Target Price
- BRTX $18.00
- CWD N/A
- AVG Volume (30 Days)
- BRTX 34.3K
- CWD 808.1K
- Earning Date
- BRTX 05-13-2025
- CWD 05-08-2025
- Dividend Yield
- BRTX N/A
- CWD N/A
- EPS Growth
- BRTX N/A
- CWD N/A
- EPS
- BRTX N/A
- CWD N/A
- Revenue
- BRTX $401,000.00
- CWD $51,119,000.00
- Revenue This Year
- BRTX $446.88
- CWD N/A
- Revenue Next Year
- BRTX $39.53
- CWD $35.72
- P/E Ratio
- BRTX N/A
- CWD N/A
- Revenue Growth
- BRTX 175.03
- CWD N/A
- 52 Week Low
- BRTX $1.03
- CWD $0.25
- 52 Week High
- BRTX $2.55
- CWD $1.04
- Technical
- Relative Strength Index (RSI)
- BRTX 46.37
- CWD 23.84
- Support Level
- BRTX $1.64
- CWD $0.22
- Resistance Level
- BRTX $1.78
- CWD $0.27
- Average True Range (ATR)
- BRTX 0.10
- CWD 0.06
- MACD
- BRTX -0.01
- CWD -0.03
- Stochastic Oscillator
- BRTX 42.82
- CWD 11.67
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
About CWD CaliberCos Inc.
CaliberCos Inc is an asset management firm, whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. Majority of revenue is derived from Asset management fees segment.